Andrea Laslop
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Andrea Laslop has a total of 349 co-authors. Here are the top co-authors by number of shared publications:
- Mário Miguel Rosa
Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, 1649-028 Lisbon, Portugal
5 shared publications - Nicholas C. Harvey
MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK
5 shared publications - René Rizzoli
Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
5 shared publications - Ali Mobasheri
Research Unit of Health Sciences and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland
4 shared publications - Jean-Yves Reginster
Protein Research Chair, Department of Biochemistry, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia
4 shared publications Nansa Burlet
Division d'Epidémiologie, Santé Publique Et Economie de La Santé, Université de Liège, Liège, Belgium
4 shared publications
Latest Publications
- 16 November 2026
- Published by Springer Nature in Nature Reviews Rheumatology
Development of treatments for sarcopenia: new challenges, opportunities and perspectives
Sarcopenia is characterized by loss of muscle mass, strength and function, and is associated with decline in physical function, falls, fractures and premature mortality. Despite increasing recognition of its clinical and societal burden, progress in translating advances in sarcopenia research into approved pharmacological therapies has remained limited. Potential barriers include heterogeneity in trial design regarding eligibility criteria, follow-up duration and outcomes, as well as limited regulatory harmonization. Given advances in sarcopenia research, the continued absence of approved treatments and the need to integrate perspectives that have emerged since the 2020 ESCEO recommendations for the conduct of sarcopenia clinical trials, this Perspective provides up-to-date expert perspectives on the development of treatments for sarcopenia, informed by discussions held by a working group convened by the World Health Organization Collaborating Centre for Epidemiology of Musculoskeletal Conditions and Ageing. Developments in the definition of sarcopenia, the regulatory landscape and therapeutic approaches are presented, together with considerations for the design of pharmacological trials, including target populations, the selection and assessment of trial outcomes (including digital health measures and patient-reported outcome measures), trial duration, use of biomarkers and patient expectations of treatments.
- 16 November 2026
- Published by Springer Nature in Nature Reviews Rheumatology
Development of treatments for sarcopenia: new challenges, opportunities and perspectives
Sarcopenia is characterized by loss of muscle mass, strength and function, and is associated with decline in physical function, falls, fractures and premature mortality. Despite increasing recognition of its clinical and societal burden, progress in translating advances in sarcopenia research into approved pharmacological therapies has remained limited. Potential barriers include heterogeneity in trial design regarding eligibility criteria, follow-up duration and outcomes, as well as limited regulatory harmonization. Given advances in sarcopenia research, the continued absence of approved treatments and the need to integrate perspectives that have emerged since the 2020 ESCEO recommendations for the conduct of sarcopenia clinical trials, this Perspective provides up-to-date expert perspectives on the development of treatments for sarcopenia, informed by discussions held by a working group convened by the World Health Organization Collaborating Centre for Epidemiology of Musculoskeletal Conditions and Ageing. Developments in the definition of sarcopenia, the regulatory landscape and therapeutic approaches are presented, together with considerations for the design of pharmacological trials, including target populations, the selection and assessment of trial outcomes (including digital health measures and patient-reported outcome measures), trial duration, use of biomarkers and patient expectations of treatments.
- Top Cited Papers
- 3 October 2025
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 21 (11) , 684-695
Novel approaches to the stratified management of knee osteoarthritis
Knee osteoarthritis is a highly prevalent whole-joint disease that is associated with substantial morbidity. If step changes are to be made in the management of knee osteoarthritis, novel patient stratification approaches are needed to identify the most effective treatment for individual patients. Numerous methods for stratifying patients with knee osteoarthritis can be employed; clinical presentation, including co-morbidity and pain phenotype, can influence treatment decisions, and there is a rich history of imaging biomarker use, both from conventional radiographs and, since its development, via MRI, in identifying patients at risk of disease progression, and the latter facilitates the detection of synovitis. The development of novel biochemical biomarkers and the rapid growth of ‘-omics’ technologies provide fresh opportunities to deploy these advances in the stratification of patients with knee osteoarthritis. The health economic landscape in this area is developing, and scoping work has highlighted the need for further studies.
- 3 October 2025
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 21 (11) , 684-695
Top Cited PapersNovel approaches to the stratified management of knee osteoarthritis
Knee osteoarthritis is a highly prevalent whole-joint disease that is associated with substantial morbidity. If step changes are to be made in the management of knee osteoarthritis, novel patient stratification approaches are needed to identify the most effective treatment for individual patients. Numerous methods for stratifying patients with knee osteoarthritis can be employed; clinical presentation, including co-morbidity and pain phenotype, can influence treatment decisions, and there is a rich history of imaging biomarker use, both from conventional radiographs and, since its development, via MRI, in identifying patients at risk of disease progression, and the latter facilitates the detection of synovitis. The development of novel biochemical biomarkers and the rapid growth of ‘-omics’ technologies provide fresh opportunities to deploy these advances in the stratification of patients with knee osteoarthritis. The health economic landscape in this area is developing, and scoping work has highlighted the need for further studies.
- Top Cited PapersOpen Access
- 28 March 2025
- Published by Springer Nature in Osteoporosis International
- Vol. 36 (4) , 579-608
Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Purpose The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) have proposed procollagen type I N propeptide (PINP) and β isomerized C-terminal telopeptide of type I collagen (β-CTX-I) as reference bone turnover markers (BTMs) for osteoporosis. This report examines the published literature since the 2011 IOF-IFCC position paper in order to determine the clinical potential of the reference BTMs and newer markers for the prediction of fracture risk and monitoring the treatment of osteoporosis. Methods Evidence for the relationship between BTMs and subsequent fractures was gathered from prospective studies through literature review of the Medline database from years 2011 to May 2024. The impact of treatment on BTMs was also studied by examining publications in that period. Studies of the accuracy of BTMs in the assessment of bone turnover in the setting of advanced chronic kidney disease were also examined. Results Increased BTM concentrations are associated with higher fracture risk in postmenopausal women. PINP and β-CTX-I measured in blood are associated with fracture risk but their interaction with other risk factors has not been sufficiently studied limiting their incorporation into fracture risk algorithms. Treatment-induced changes in PINP and β-CTX-I account for a substantial proportion of fracture risk reduction and are useful for improving adherence; they are recommended for inclusion in studies to examine adherence in individual patients. However, total PINP (tPINP) and β-CTX-I may be elevated in CKD due to renal retention. Bone alkaline phosphatase (BALP), intact PINP (iPINP), and tartrate resistant acid phosphatase 5b (TRACP5b) show the most promise in discriminating high and low turnover bone diseases in patients with advanced CKD and for predicting fracture risk, monitoring treatment response, and assessing the risk of treatment-related complications. Conclusion We re-affirm the use of serum/plasma tPINP and plasma β-CTX-I as reference BTMs with appropriate patient preparation and sample handling and measurement by standardized/harmonized assays in clinical studies to accumulate further data, and for monitoring treatment of osteoporosis in the setting of normal renal function in clinical practice. BALP and TRACP5b, measured by standardized assays, are recommended as reference BTMs for CKD-associated osteoporosis and should be included in observational and intervention studies to ascertain their utility for risk-evaluation, treatment initiation, and assessment of treatment response in CKD-associated osteoporosis.
- 28 March 2025
- Published by Springer Nature in Osteoporosis International
- Vol. 36 (4) , 579-608
Top Cited PapersOpen AccessUpdate on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), International Osteoporosis Foundation (IOF), and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)
Purpose The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) have proposed procollagen type I N propeptide (PINP) and β isomerized C-terminal telopeptide of type I collagen (β-CTX-I) as reference bone turnover markers (BTMs) for osteoporosis. This report examines the published literature since the 2011 IOF-IFCC position paper in order to determine the clinical potential of the reference BTMs and newer markers for the prediction of fracture risk and monitoring the treatment of osteoporosis. Methods Evidence for the relationship between BTMs and subsequent fractures was gathered from prospective studies through literature review of the Medline database from years 2011 to May 2024. The impact of treatment on BTMs was also studied by examining publications in that period. Studies of the accuracy of BTMs in the assessment of bone turnover in the setting of advanced chronic kidney disease were also examined. Results Increased BTM concentrations are associated with higher fracture risk in postmenopausal women. PINP and β-CTX-I measured in blood are associated with fracture risk but their interaction with other risk factors has not been sufficiently studied limiting their incorporation into fracture risk algorithms. Treatment-induced changes in PINP and β-CTX-I account for a substantial proportion of fracture risk reduction and are useful for improving adherence; they are recommended for inclusion in studies to examine adherence in individual patients. However, total PINP (tPINP) and β-CTX-I may be elevated in CKD due to renal retention. Bone alkaline phosphatase (BALP), intact PINP (iPINP), and tartrate resistant acid phosphatase 5b (TRACP5b) show the most promise in discriminating high and low turnover bone diseases in patients with advanced CKD and for predicting fracture risk, monitoring treatment response, and assessing the risk of treatment-related complications. Conclusion We re-affirm the use of serum/plasma tPINP and plasma β-CTX-I as reference BTMs with appropriate patient preparation and sample handling and measurement by standardized/harmonized assays in clinical studies to accumulate further data, and for monitoring treatment of osteoporosis in the setting of normal renal function in clinical practice. BALP and TRACP5b, measured by standardized assays, are recommended as reference BTMs for CKD-associated osteoporosis and should be included in observational and intervention studies to ascertain their utility for risk-evaluation, treatment initiation, and assessment of treatment response in CKD-associated osteoporosis.
- Open Access
- 27 December 2024
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 37 (1) , 1-22
Impact of dementia and mild cognitive impairment on bone health in older people
Mild cognitive impairment, dementia and osteoporosis are common diseases of ageing and, with the increasingly ageing global population, are increasing in prevalence. These conditions are closely associated, with shared risk factors, common underlying biological mechanisms and potential direct causal pathways. In this review, the epidemiological and mechanistic links between mild cognitive impairment, dementia and skeletal health are explored. Discussion will focus on how changes in brain and bone signalling can underly associations between these conditions, and will consider the molecular and cellular drivers in the context of inflammation and the gut microbiome. There is a complex interplay between nutritional changes, which may precede or follow the onset of mild cognitive impairment (MCI) or dementia, and bone health. Polypharmacy is common in patients with MCI or dementia, and there are difficult prescribing decisions to be made due to the elevated risk of falls associated with many drugs used for associated problems, which can consequently increase fracture risk. Some medications prescribed for cognitive impairment may directly impact bone health. In addition, patients may have difficulty remembering medication without assistance, meaning that osteoporosis drugs may be prescribed but not taken. Cognitive impairment may be improved or delayed by physical activity and exercise, and there is evidence for the additional benefits of physical activity on falls and fractures. Research gaps and priorities with the aim of reducing the burden of osteoporosis and fractures in people with MCI or dementia will also be discussed.
- 27 December 2024
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 37 (1) , 1-22
Open AccessImpact of dementia and mild cognitive impairment on bone health in older people
Mild cognitive impairment, dementia and osteoporosis are common diseases of ageing and, with the increasingly ageing global population, are increasing in prevalence. These conditions are closely associated, with shared risk factors, common underlying biological mechanisms and potential direct causal pathways. In this review, the epidemiological and mechanistic links between mild cognitive impairment, dementia and skeletal health are explored. Discussion will focus on how changes in brain and bone signalling can underly associations between these conditions, and will consider the molecular and cellular drivers in the context of inflammation and the gut microbiome. There is a complex interplay between nutritional changes, which may precede or follow the onset of mild cognitive impairment (MCI) or dementia, and bone health. Polypharmacy is common in patients with MCI or dementia, and there are difficult prescribing decisions to be made due to the elevated risk of falls associated with many drugs used for associated problems, which can consequently increase fracture risk. Some medications prescribed for cognitive impairment may directly impact bone health. In addition, patients may have difficulty remembering medication without assistance, meaning that osteoporosis drugs may be prescribed but not taken. Cognitive impairment may be improved or delayed by physical activity and exercise, and there is evidence for the additional benefits of physical activity on falls and fractures. Research gaps and priorities with the aim of reducing the burden of osteoporosis and fractures in people with MCI or dementia will also be discussed.
- Top Cited PapersOpen Access
- 14 March 2024
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 20 (4) , 241-251
Evidence-Based Guideline for the management of osteoporosis in men
Historically, osteoporosis has been viewed as a disease of women, with research, trials of interventions and guidelines predominantly focused as such. It is apparent, however, that this condition causes a substantial health burden in men also, and that its assessment and management must ultimately be addressed across both sexes. In this article, an international multidisciplinary working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases presents GRADE-assessed recommendations for the diagnosis, monitoring and treatment of osteoporosis in men. The recommendations are based on a comprehensive review of the latest research related to diagnostic and screening approaches for osteoporosis and its associated high fracture risk in men, covering disease burden, appropriate interpretation of bone densitometry (including the use of a female reference database for densitometric diagnosis in men) and absolute fracture risk, thresholds for treatment, and interventions that can be used therapeutically and their health economic evaluation. Future work should specifically address the efficacy of anti-osteoporosis medications, including denosumab and bone-forming therapies.
- 14 March 2024
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 20 (4) , 241-251
Top Cited PapersOpen AccessEvidence-Based Guideline for the management of osteoporosis in men
Historically, osteoporosis has been viewed as a disease of women, with research, trials of interventions and guidelines predominantly focused as such. It is apparent, however, that this condition causes a substantial health burden in men also, and that its assessment and management must ultimately be addressed across both sexes. In this article, an international multidisciplinary working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases presents GRADE-assessed recommendations for the diagnosis, monitoring and treatment of osteoporosis in men. The recommendations are based on a comprehensive review of the latest research related to diagnostic and screening approaches for osteoporosis and its associated high fracture risk in men, covering disease burden, appropriate interpretation of bone densitometry (including the use of a female reference database for densitometric diagnosis in men) and absolute fracture risk, thresholds for treatment, and interventions that can be used therapeutically and their health economic evaluation. Future work should specifically address the efficacy of anti-osteoporosis medications, including denosumab and bone-forming therapies.
- Open Access
- 15 June 2016
- Published by Pro Pharma Communications International in Generics and Biosimilars Initiative Journal
- Vol. 5 (2) , 74-83
Roundtable on biosimilars with European regulators and medical societies, Brussels, Belgium, 12 January 2016
Authors byline as per print journal:Vito Annese, MD, PhD; Cristina Avendaño-Solá, MD, PhD; Professor Ferdinand Breedveld, MD; Niklas Ekman, PhD; Thijs J Giezen,
- 15 June 2016
- Published by Pro Pharma Communications International in Generics and Biosimilars Initiative Journal
- Vol. 5 (2) , 74-83
Open AccessRoundtable on biosimilars with European regulators and medical societies, Brussels, Belgium, 12 January 2016
Authors byline as per print journal:Vito Annese, MD, PhD; Cristina Avendaño-Solá, MD, PhD; Professor Ferdinand Breedveld, MD; Niklas Ekman, PhD; Thijs J Giezen,
- 1 December 2004
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 12 (12)
Volume 12 Contents index
- 1 December 2004
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 12 (12)
Volume 12 Contents index